Your session is about to expire
← Back to Search
Prostate Cancer Genius App Education for Prostate Cancer (PCGA Trial)
N/A
Waitlist Available
Led By Adam Alexander, PhD
Research Sponsored by University of Oklahoma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
are between the ages of 55 and 69
self-identify as "male" and "Black or African American"
Must not have
Currently or previously diagnosed with prostate cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30-days
Awards & highlights
No Placebo-Only Group
Summary
This trial tests the Prostate Cancer Genius App, designed to educate African American men about prostate cancer and help them complete a home-based PSA test. The study involves men aged 55 to 69 from Oklahoma who haven't had a PSA test in a while. The app aims to increase knowledge and screening rates by providing tailored information and guidance.
Who is the study for?
This trial is for African American men aged 55-69 living in Oklahoma who haven't had a PSA screening for prostate cancer in the last two years and have never been diagnosed with prostate cancer.
What is being tested?
The study is testing the Prostate Cancer Genius App against an existing health app to see if it improves knowledge about prostate cancer risk, encourages home-based PSA testing, and is user-friendly over a period of 30 days.
What are the potential side effects?
Since this trial involves educational apps rather than medical treatments, there are no direct physical side effects. However, participants may experience stress or anxiety related to learning about their potential cancer risk.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 55 and 69 years old.
Select...
I am a Black or African American male.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have been diagnosed with prostate cancer.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30-days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30-days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Prostate Cancer Knowledge
Secondary study objectives
PSA screening test completion rates
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Prostate Cancer Genius appExperimental Treatment1 Intervention
The Prostate Cancer Genius app includes the following components: (1) educational content that is consistent with existing evidence and recommendations for prostate cancer and prostate cancer screening but has been adapted for the African American male population and for adults who read at or below the 8th-grade level; (2) real-time messages about the risks of prostate cancer and the benefits of completing a PSA test, placing a special emphasis on screening considerations for individuals with a family history of prostate cancer and/or lower urinary tract symptoms (measured via the American Urological Association Symptom Score); (3) general trivia that also incorporates quiz questions about prostate cancer and the PSA test; (4) African American-specific testimonials and educational videos; (5) optional counseling by African American prostate cancer survivors; and (6) on-demand, automated ordering of a home-based PSA test.
Group II: Prevention Taskforce appActive Control1 Intervention
The Prevention Taskforce app provides on-demand access to evidence-based recommendations for prostate cancer for men between 55 and 69 (i.e., it can be accessed as needed).
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for prostate cancer, particularly advanced stages, include androgen deprivation therapy (ADT), which works by lowering serum testosterone levels to inhibit cancer growth. This can be achieved through surgical castration or medications like luteinizing hormone-releasing hormone (LHRH) agonists and antagonists.
Additionally, antiandrogens block the action of testosterone on prostate cancer cells. These treatments are crucial as they help manage symptoms, slow disease progression, and improve survival rates.
Understanding these mechanisms is vital for patients, as it underscores the importance of regular monitoring through PSA testing, which can be facilitated by digital platforms like the Prostate Cancer Genius App.
Choosing the right treatment for patients with psoriatic arthritis.Molecular therapeutics in prostate cancer.
Choosing the right treatment for patients with psoriatic arthritis.Molecular therapeutics in prostate cancer.
Find a Location
Who is running the clinical trial?
University of OklahomaLead Sponsor
473 Previous Clinical Trials
93,601 Total Patients Enrolled
4 Trials studying Health Behaviors
623 Patients Enrolled for Health Behaviors
Adam Alexander, PhDPrincipal InvestigatorTSET Health Promotion Research Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am between 55 and 69 years old.I have been diagnosed with prostate cancer.I am a Black or African American male.
Research Study Groups:
This trial has the following groups:- Group 1: Prostate Cancer Genius app
- Group 2: Prevention Taskforce app
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger